HONG KONG – Terns Pharmaceuticals Inc., a company based in China and the U.S., entered a licensing and collaboration agreement with French company Genfit SA to develop and commercialize elafibranor, in development for nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC).